Clinical trial

VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or…

NCT00036946 · Regeneron Pharmaceuticals, Industry · Completed

Key facts

NCT number NCT00036946
Title VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma
Official title An Open-Label, Sequential Cohort Dose-Escalation Safety, Tolerability And Pharmacokinetic Study Of VEGF Trap In Patients With Incurable, Relapsed Or Refractory Solid Tumors Or Lymphoma
Lead sponsor Regeneron Pharmaceuticals, Industry
Collaborators National Cancer Institute (NCI) NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Intervention type Biological
Interventions ziv-aflibercept
Start date Nov 1, 2001
Primary completion Mar 1, 2002
First posted Jan 27, 2003
Last update posted Jun 3, 2016
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies